Press release
November 2, 2026
Celanese Corporation Reports Third Quarter Earnings; Exceeds Third Quarter Guidance and Raises Full Year Outlook
Celanese Corp (CE)
Back to news
Mon, November 02 2026
DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported third quarter 2026 U.S. GAAP diluted earnings per share of $0.68 and adjusted earnings per share of $1.65. Net sales of $2.6 billion increased 6 percent compared to the same period in 2025 and were driven by progress on strategic growth initiatives and commercial actions across the portfolio. Sequentially, net sales decreased 7 percent, reflecting expected moderation from the second quarter.
For the third quarter, the Company reported consolidated operating profit of $198 million, adjusted EBIT of $367 million, and operating EBITDA of $548 million at margins of 8, 14, and 21 percent, respectively. These results reflect disciplined execution across the Company, commercial execution, and the resilience of the Company's differentiated businesses.
Celanese has continued to take actions that demonstrate its ability to improve earnings while generating substantial cash flow to drive meaningful progress on deleveraging. In the third quarter, the Company delivered operating cash flow of $538 million and free cash flow of $461 million.
"Our third quarter results demonstrate continued progress across Celanese, with strong earnings performance and net sales growth," said Scott Richardson, president and chief executive officer. "Cash generation in the third quarter was strong, and by the end of 2026 we expect to have generated over $1.5 billion in free cash flow over the past two years, reflecting the benefits of the significant actions we have taken to improve productivity, strengthen commercial execution and enhance the quality of our portfolio. We also continue to advance our objective of generating approximately $1 billion of divestiture sales proceeds by the end of 2027, and expect to reach approximately $650 million by year end. The benefits of our productivity actions and early contributions from strategic growth initiatives are increasingly evident in our results, enhancing earnings quality, strengthening cash generation, and accelerating progress on deleveraging."
Third Quarter 2026 Financial Highlights:
Three Months Ended
September 30,
2026
June 30,
2026
September 30,
2025
(unaudited)
(In $ millions, except per share data)
Net Sales
Engineered Materials
1,368
1,446
1,384
Acetyl Chain
1,209
1,329
1,061
Intersegment Eliminations
(21
)
(23
)
(26
)
Total
2,556
2,752
2,419
Operating Profit (Loss)
Engineered Materials
161
156
(1,327
)
Acetyl Chain
141
237
135
Other Activities
(104
)
(117
)
(83
)
Total
198
276
(1,275
)
Net Earnings (Loss)
78
129
(1,353
)
Adjusted EBIT (1)
Engineered Materials
209
234
200
Acetyl Chain
236
321
187
Other Activities
(78
)
(85
)
(61
)
Total
367
470
326
Equity Earnings and Dividend Income
Engineered Materials
3
6
33
Acetyl Chain
47
44
43
Operating EBITDA (1)
548
649
517
Diluted EPS - continuing operations
$
0.68
$
1.15
$
(12.39
)
Diluted EPS - total
$
0.67
$
1.13
$
(12.39
)
Adjusted EPS (1)
$
1.65
$
2.45
$
1.34
Net cash provided by (used in) investing activities
(70
)
(59
)
(59
)
Net cash provided by (used in) financing activities
(480
)
(546
)
(118
)
Net cash provided by (used in) operating activities
538
209
447
Free cash flow (1)
461
140
5
______________________________
(1)
See "Non-US GAAP Financial Measures" below.
Recent Highlights:
Announced an Investor Event to take place on December 9, 2026 at the Company's technical center and manufacturing site in Florence, Kentucky. Executive management plans to provide details on the Company’s business strategy, growth pathways, and long-term value creation priorities.
Added Luis Fernandez-Moreno to the Company’s Board of Directors in September 2026. Mr. Fernandez-Moreno most recently served as interim President and Chief Executive officer of Ingevity Corporation, and previously as Senior Vice President at Ashland, Inc. Prior to that, he held various leadership roles at Arch Chemicals, The Dow Chemical Company, and Rohm & Haas Company. Mr. Fernandez-Moreno brings over 40 years of experience and leadership in the performance materials, specialty ingredients and coatings industries spanning corporate strategy, growth and innovation, and mergers and acquisitions.
Signed a definitive agreement to sell an additional 19 percent of the Nutrinova food ingredients joint venture to Mitsui & Co., Ltd. in a transaction with total cash proceeds of approximately $152 million, while retaining 11 percent interest in the joint venture. The Company expects the transaction to close in the fourth quarter of 2026, subject to certain regulatory approvals and other customary closing conditions.
Entered into a strategic partnership with VIGOR Precision Ltd., a global leader in precision plastic gears and components, to advance the development and commercialization of lightweight plastic joint solutions for humanoid robots. This further expands Celanese's targeted growth opportunities.
Completed the previously announced closure of the acetate tow facility in Lanaken, Belgium to further optimize the Company's manufacturing footprint and cost structure. Celanese has successfully leveraged existing resources to continue to meet the needs and expectations of customers.
Third Quarter Business Segment Overview
Engineered Materials
Engineered Materials reported third quarter net sales of $1.4 billion, a 1 percent decrease year over year; however, 2025 sales included the divested Micromax ® business that contributed 6 percent to the year over year decline. The results reflected continued momentum in the business's strategic growth initiatives and disciplined commercial execution. Growth in medical and electronics applications continued to support favorable mix enrichment and earnings improvement during the quarter. Sequentially, net sales declined 5 percent, mainly driven by sequential automotive declines partially offset by strength in medical and electronics. The business reported third quarter operating profit of $161 million, adjusted EBIT of $209 million, and operating EBITDA of $311 million, with margins of 12, 15, and 23 percent, respectively. Results were supported by strong commercial execution, favorable product mix, and early contributions from a number of strategic growth initiatives, which more than offset raw material inflation and higher logistics costs. The business continues to make meaningful progress in advancing a number of targeted initiatives that support both growth and competitiveness, with progress of the planned expansions of specialty compounding operations in Europe, beginning commissioning activities for the liquid crystal polymer production facility in Asia, and advancing new medical-grade compounding capabilities in Asia. The business remains on track to commercialize all three projects during the first half of 2027.
Acetyl Chain
The Acetyl Chain reported third quarter net sales of $1.2 billion, a 14 percent increase compared to the same period in 2025. During the quarter, the Acetyl Chain delivered strong performance across acetic acid, derivatives, and the vinyls chain, as modest demand softness was more than offset by pricing favorability and incremental spot opportunities. Sequentially, net sales declined 9 percent, reflecting anticipated moderation from normalizing supply chains. The quarter developed largely as expected and reflected continued strength across the business despite periods of volatility. The business delivered third quarter operating profit of $141 million, adjusted EBIT of $236 million, and operating EBITDA of $301 million at margins of 12, 20, and 25 percent, respectively. Performance in the quarter once again highlighted the strength of the Acetyl Chain's integrated business model, the benefits of its flexible operating network, and its ability to capture value across regions in a dynamic environment.
Cash Flow and Tax
Celanese reported third quarter operating cash flow of $538 million and free cash flow of $461 million, with year to date operating cash flow of $823 million and free cash flow of $604 million, supported by anticipated working capital timing benefits and continued discipline in capital expenditures.
The effective U.S. GAAP income tax rate for the third quarter was 15 percent, higher than same period in 2025, primarily due to a non-cash goodwill impairment loss of $1.1 billion in the Engineered Materials segment recorded during the prior year, which is not deductible for tax purposes. The effective tax rate for 2026 adjusted earnings was 8 percent for the third quarter, and we anticipate this rate for the full year 2026 based on expected full year jurisdictional earnings mix and consideration of other non-recurring U.S. GAAP items.
Outlook
"Looking to the fourth quarter, we expect year-end seasonal moderation across both businesses. We will continue to drive our strategic initiatives, our targeted growth areas, as well as our cost reduction and productivity programs," continued Richardson. "Based on these dynamics, we anticipate full-year 2026 adjusted earnings per share of approximately $6.00 to $6.25. In addition, based on our strong execution year to date, we have increased our free cash flow outlook to a range of $750 to $800 million."
"While conditions remain dynamic, the progress we are seeing across our productivity initiatives, strategic growth platforms, and cash generation efforts give us confidence in our ability to continue improving the earnings power of the company over time. We also expect to exit the year with net debt-to-operating EBITDA of approximately 4.7x, reflecting the progress we have made on deleveraging through disciplined cash generation, targeted divestitures, and focused capital allocation. We remain focused on continuing to strengthen the balance sheet, improving the quality and durability of earnings, and creating long-term shareholder value through disciplined execution of our growth and strategic initiatives," Richardson concluded.
Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT, operating EBITDA or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.
The Company's prepared remarks related to the third quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on November 2, 2026. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.
Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs more than 11,000 employees worldwide with 2025 net sales of $9.5 billion.
Forward-Looking Statements
This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, deleveraging efforts, planned cost reductions, dividend policy, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: the ability to successfully achieve planned cost reductions; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities, in the countries in which we operate; our level of indebtedness and our financial condition, each of which could diminish our ability to raise additional capital to fund operations, reduce our business and strategic flexibility, increase our interest expense, limit the success of our deleveraging efforts, and impact changes to our credit ratings, which could increase our interest expense in the event of additional downgrades; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine, Polyamide 66 ("PA66"), polybutylene terephthalate, ethanol, natural gas and fuel oil, and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to realize the anticipated benefits of the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition"), including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; additional impairment of goodwill or intangible assets; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, AI-related vulnerabilities, terrorism or political unrest, public health crises, or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia-Ukraine conflict or conflicts in the Middle East) or terrorist incidents or as a result of fire, flood, hurricanes, other severe weather, natural disasters, other catastrophic events, or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties, treaties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; changes in currency exchange rates and interest rates; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.
Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
Non-GAAP Financial Measures
Presentation
This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.
Use of Non-US GAAP Financial Information
This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for operating EBITDA margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.
Definitions of Non-US GAAP Financial Measures
Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.
Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We do not provide reconciliations for operating EBITDA on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales.
Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our noncontrolling interest joint ventures. We do not provide reconciliations for free cash flow on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Reconciliation of Non-US GAAP Financial Measures
Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about November 2, 2026 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
Beginning with the reporting period ending June 30, 2026, the Company revised its presentation of Equity Earnings and Dividend Income Attributable to Celanese Corporation. Previously, Other Income (Expense) Attributable to Celanese Corporation was included with the presentation of Equity Earnings and Dividend Income Attributable to Celanese Corporation. To provide a better understanding for readers of the U.S. GAAP results of the Company’s non-consolidated equity investments by presenting such results in isolation and better align with how management assesses such results, Other Income (Expense) Attributable to Celanese Corporation is now included with Non-Operating Pension, Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation. Prior periods presented have been revised to reflect this change.
Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2026.
Supplemental Information
Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.
Consolidated Statements of Operations - Unaudited
Three Months Ended
September 30,
2026
June 30,
2026
September 30,
2025
(In $ millions, except share and per share data)
Net sales
2,556
2,752
2,419
Cost of sales
(2,017
)
(2,134
)
(1,898
)
Gross profit
539
618
521
Selling, general and administrative expenses
(248
)
(251
)
(231
)
Amortization of intangible assets
(40
)
(39
)
(42
)
Research and development expenses
(29
)
(29
)
(31
)
Other (charges) gains, net
(32
)
(31
)
(1,491
)
Foreign exchange gain (loss), net
12
10
2
Gain (loss) on disposition of businesses and assets, net
(4
)
(2
)
(3
)
Operating profit (loss)
198
276
(1,275
)
Equity in net earnings (loss) of affiliates
9
11
39
Non-operating pension and other postretirement employee benefit (expense) income
5
5
2
Interest expense
(175
)
(186
)
(177
)
Interest income
6
10
7
Dividend income - equity investments
44
43
40
Other income (expense), net
6
(17
)
4
Earnings (loss) from continuing operations before tax
93
142
(1,360
)
Income tax (provision) benefit
(14
)
(11
)
7
Earnings (loss) from continuing operations
79
131
(1,353
)
Earnings (loss) from operation of discontinued operations
(2
)
(2
)
—
Income tax (provision) benefit from discontinued operations
1
—
—
Earnings (loss) from discontinued operations
(1
)
(2
)
—
Net earnings (loss)
78
129
(1,353
)
Net (earnings) loss attributable to noncontrolling interests
(4
)
(4
)
(4
)
Net earnings (loss) attributable to Celanese Corporation
74
125
(1,357
)
Amounts attributable to Celanese Corporation
Earnings (loss) from continuing operations
75
127
(1,357
)
Earnings (loss) from discontinued operations
(1
)
(2
)
—
Net earnings (loss)
74
125
(1,357
)
Earnings (loss) per common share - basic
Continuing operations
0.68
1.16
(12.39
)
Discontinued operations
(0.01
)
(0.02
)
—
Net earnings (loss) - basic
0.67
1.14
(12.39
)
Earnings (loss) per common share - diluted
Continuing operations
0.68
1.15
(12.39
)
Discontinued operations
(0.01
)
(0.02
)
—
Net earnings (loss) - diluted
0.67
1.13
(12.39
)
Weighted average shares (in millions)
Basic
109.8
109.8
109.6
Diluted
110.2
110.2
109.6
Consolidated Balance Sheets - Unaudited
As of
September 30,
2026
As of
December 31,
2025
(In $ millions)
ASSETS
Current Assets
Cash and cash equivalents
1,362
1,263
Trade receivables - third party and affiliates, net
960
922
Non-trade receivables, net
624
545
Inventories
2,286
2,220
Assets held for sale
—
492
Other assets
258
251
Total current assets
5,490
5,693
Investments in affiliates
1,267
1,252
Property, plant and equipment, net
4,715
5,076
Operating lease right-of-use assets
426
359
Deferred income taxes
1,279
1,359
Other assets
571
601
Goodwill
4,150
4,171
Intangible assets, net
3,036
3,184
Total assets
20,934
21,695
LIABILITIES AND EQUITY
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates
1,414
1,204
Trade payables - third party and affiliates
1,315
1,279
Liabilities held for sale
—
75
Other liabilities
1,479
1,049
Income taxes payable
142
76
Total current liabilities
4,350
3,683
Long-term debt, net of unamortized deferred financing costs
10,131
11,394
Deferred income taxes
369
512
Uncertain tax positions
222
208
Benefit obligations
312
344
Operating lease liabilities
329
265
Other liabilities
586
817
Commitments and Contingencies
Shareholders' Equity
Treasury stock, at cost
(5,480
)
(5,482
)
Additional paid-in capital
459
431
Retained earnings
10,109
9,876
Accumulated other comprehensive income (loss), net
(872
)
(776
)
Total Celanese Corporation shareholders' equity
4,216
4,049
Noncontrolling interests
419
423
Total equity
4,635
4,472
Total liabilities and equity
20,934
21,695
Non-U.S. GAAP Financial Measures and Supplemental Information
November 2, 2026
In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.
Purpose
The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-U.S. GAAP financial measures. This document is updated quarterly.
Presentation
This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.
Use of Non-U.S. GAAP Financial Measures
From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with U.S. GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable U.S. GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.
Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other U.S. GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.
Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.
This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.
Specific Measures Used
This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with U.S. GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity.
Definitions
Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as adjusted EBIT.
Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. We do not provide reconciliations for operating EBITDA on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as operating EBITDA.
Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as operating profit (loss) attributable to Celanese Corporation.
Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures. We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure. We do not provide reconciliations for free cash flow on a forward-looking basis when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our shareholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.
Supplemental Information
Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:
Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
Cash dividends received from our equity investments.
For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as NCI. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
Beginning with the reporting period ending June 30, 2026, the Company revised its presentation of Equity Earnings and Dividend Income Attributable to Celanese Corporation. Previously, Other Income (Expense) Attributable to Celanese Corporation was included with the presentation of Equity Earnings and Dividend Income Attributable to Celanese Corporation. To provide a better understanding for readers of the U.S. GAAP results of the Company’s non-consolidated equity investments by presenting such results in isolation and better align with how management assesses such results, Other Income (Expense) Attributable to Celanese Corporation is now included with Non-Operating Pension, Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation. Prior periods presented have been revised to reflect this change.
Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2026.
Table 1
Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions)
Net earnings (loss) attributable to Celanese Corporation
74
125
44
(1,165
)
19
(1,357
)
197
(24
)
(Earnings) loss from discontinued operations
1
2
1
21
6
—
10
5
Interest income
(6
)
(10
)
(9
)
(24
)
(6
)
(7
)
(7
)
(4
)
Interest expense
175
186
183
701
177
177
177
170
Refinancing expense
—
—
—
68
36
—
—
32
Income tax provision (benefit)
14
11
33
(90
)
(15
)
(7
)
(77
)
9
Certain Items attributable to Celanese Corporation (Table 8)
109
156
23
1,639
34
1,520
42
43
Adjusted EBIT
367
470
275
1,150
251
326
342
231
Depreciation and amortization expense (1)
181
179
180
743
184
191
188
180
Operating EBITDA
548
649
455
1,893
435
517
530
411
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions)
Engineered Materials
11
43
3
6
1
3
2
—
Acetyl Chain
18
22
18
11
11
—
—
—
Other Activities (2)
—
—
—
—
—
—
—
—
Accelerated depreciation and amortization expense
29
65
21
17
12
3
2
—
Depreciation and amortization expense (1)
181
179
180
743
184
191
188
180
Total depreciation and amortization expense
210
244
201
760
196
194
190
180
______________________________
(1)
Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.
(2)
Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, and treasury operations, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
Table 2
Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions, except percentages)
Operating Profit (Loss) / Operating Margin
Engineered Materials
161
11.8
%
156
10.8
%
221
16.7
%
(958
)
(17.8
)%
111
8.7
%
(1,327
)
(95.9
)%
164
11.4
%
94
7.3
%
Acetyl Chain
141
11.7
%
237
17.8
%
95
9.2
%
539
12.7
%
90
9.6
%
135
12.7
%
153
13.7
%
161
14.4
%
Other Activities (1)
(104
)
(117
)
(102
)
(367
)
(108
)
(83
)
(86
)
(90
)
Total
198
7.7
%
276
10.0
%
214
9.2
%
(786
)
(8.2
)%
93
4.2
%
(1,275
)
(52.7
)%
231
9.1
%
165
6.9
%
Less: Net Earnings (Loss) Attributable to NCI for Engineered Materials
2
2
2
6
—
3
1
2
Less: Net Earnings (Loss) Attributable to NCI for Acetyl Chain
2
2
2
8
3
1
2
2
Operating Profit (Loss) Attributable to Celanese Corporation
194
7.6
%
272
9.9
%
210
9.0
%
(800
)
(8.4
)%
90
4.1
%
(1,279
)
(52.9
)%
228
9.0
%
161
6.7
%
Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation
Engineered Materials
159
11.6
%
154
10.7
%
219
16.5
%
(964
)
(17.9
)%
111
8.7
%
(1,330
)
(96.1
)%
163
11.3
%
92
7.1
%
Acetyl Chain
139
11.5
%
235
17.7
%
93
9.0
%
531
12.5
%
87
9.3
%
134
12.6
%
151
13.5
%
159
14.2
%
Other Activities (1)
(104
)
(117
)
(102
)
(367
)
(108
)
(83
)
(86
)
(90
)
Total
194
7.6
%
272
9.9
%
210
9.0
%
(800
)
(8.4
)%
90
4.1
%
(1,279
)
(52.9
)%
228
9.0
%
161
6.7
%
Equity Earnings and Dividend Income Attributable to Celanese Corporation
Engineered Materials
3
(2)
6
(2)
31
105
32
33
24
16
Acetyl Chain
47
44
2
131
42
43
43
3
Other Activities (1)
3
4
3
13
3
3
3
4
Total
53
54
36
249
77
79
70
23
Non-Operating Pension, Other Post-Retirement Employee Benefit and Other Income (Expense) Attributable to Celanese Corporation
Engineered Materials
4
(16
)
1
7
3
2
1
1
Acetyl Chain
1
—
—
1
—
1
—
—
Other Activities (1)
6
4
5
54
47
3
1
3
Total
11
(12
)
6
62
50
6
2
4
Certain Items Attributable to Celanese Corporation (Table 8)
Engineered Materials
43
90
(31
)
1,572
37
1,495
25
15
Acetyl Chain
49
42
36
32
17
9
1
5
Other Activities (1)
17
24
18
35
(20
)
16
16
23
Total
109
156
23
1,639
34
1,520
42
43
Adjusted EBIT / Adjusted EBIT Margin
Engineered Materials
209
15.3
%
234
16.2
%
220
16.6
%
720
13.4
%
183
14.3
%
200
14.5
%
213
14.8
%
124
9.6
%
Acetyl Chain
236
19.5
%
321
24.2
%
131
12.6
%
695
16.4
%
146
15.5
%
187
17.6
%
195
17.5
%
167
15.0
%
Other Activities (1)
(78
)
(85
)
(76
)
(265
)
(78
)
(61
)
(66
)
(60
)
Total
367
14.4
%
470
17.1
%
275
11.8
%
1,150
12.0
%
251
11.4
%
326
13.5
%
342
13.5
%
231
9.7
%
___________________________
(1)
Other Activities includes corporate SG&A expenses, and treasury operations, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
(2)
Includes $11 million and $14 million of restructuring activities at our Mylar Specialty Films strategic affiliate during the three months ended September 30, 2026 and June 30, 2026, respectively, which are also included in Certain Items (see Table 8).
Table 2
Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions, except percentages)
Depreciation and Amortization Expense (1)
Engineered Materials
102
101
104
441
105
115
112
109
Acetyl Chain
65
64
63
252
64
63
64
61
Other Activities (2)
14
14
13
50
15
13
12
10
Total
181
179
180
743
184
191
188
180
Operating EBITDA / Operating EBITDA Margin
Engineered Materials
311
22.7
%
335
23.2
%
324
24.5
%
1,161
21.5
%
288
22.6
%
315
22.8
%
325
22.5
%
233
18.1
%
Acetyl Chain
301
24.9
%
385
29.0
%
194
18.7
%
947
22.4
%
210
22.3
%
250
23.6
%
259
23.2
%
228
20.4
%
Other Activities (2)
(64
)
(71
)
(63
)
(215
)
(63
)
(48
)
(54
)
(50
)
Total
548
21.4
%
649
23.6
%
455
19.5
%
1,893
19.8
%
435
19.7
%
517
21.4
%
530
20.9
%
411
17.2
%
___________________________
(1)
Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.
(2)
Other Activities includes corporate SG&A expenses, and treasury operations, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
Table 3
Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
per share
per share
per share
per share
per share
per share
per share
per share
(In $ millions, except per share data)
Earnings (loss) from continuing operations attributable to Celanese Corporation
75
0.68
127
1.15
45
0.41
(1,144
)
(10.44
)
25
0.23
(1,357
)
(12.39
)
207
1.89
(19
)
(0.17
)
Income tax provision (benefit)
14
11
33
(90
)
(15
)
(7
)
(77
)
9
Earnings (loss) from continuing operations before tax
89
138
78
(1,234
)
10
(1,364
)
130
(10
)
Certain Items attributable to Celanese Corporation (Table 8)
109
156
23
1,639
34
1,520
42
43
Refinancing and related expenses
—
—
—
68
36
—
—
32
Adjusted earnings (loss) from continuing operations before tax
198
294
101
473
80
156
172
65
Income tax (provision) benefit on adjusted earnings (1)
(16
)
(24
)
(8
)
(36
)
(6
)
(9
)
(15
)
(6
)
Adjusted earnings (loss) from continuing operations (2)
182
1.65
270
2.45
93
0.85
437
3.98
74
0.67
147
1.34
157
1.43
59
0.54
Diluted shares (in millions) (3)
Weighted average shares outstanding
109.8
109.8
109.7
109.5
109.6
109.6
109.5
109.4
Incremental shares attributable to equity awards
0.4
0.4
0.3
0.2
0.2
—
0.2
—
Total diluted shares
110.2
110.2
110.0
109.7
109.8
109.6
109.7
109.4
______________________________
(1)
Calculated using adjusted effective tax rates (Table 3a) as follows:
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
Adjusted effective tax rate
8
8
8
8
8
6
9
9
(2)
Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.
Actual Plan Asset Returns
Expected Plan Asset Returns
(In percentages)
2025
7.8
5.3
(3)
Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.
Table 3a
Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited
Estimated
Actual
2026
2025
(In percentages)
U.S. GAAP annual effective tax rate
19
7
Discrete quarterly recognition of GAAP items (1)
1
17
Tax impact of other charges and adjustments (2)
(5
)
(12
)
Utilization of foreign tax credits
(1
)
—
Changes in valuation allowances, excluding impact of other charges and adjustments (3)
(1
)
(12
)
Other, includes effect of discrete current year transactions (4)
(5
)
8
Adjusted tax rate
8
8
______________________________
Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.
(1)
Such as changes in tax laws (including U.S. tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.
(2)
Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.
(3)
Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.
(4)
Includes tax impacts related to full-year actual tax opportunities and related costs, as well as current year realization of U.S. GAAP benefits deferred in prior years.
Table 4
Net Sales by Segment - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions)
Engineered Materials
1,368
1,446
1,325
5,390
1,277
1,384
1,442
1,287
Acetyl Chain
1,209
1,329
1,036
4,232
940
1,061
1,115
1,116
Intersegment eliminations (1)
(21
)
(23
)
(24
)
(78
)
(13
)
(26
)
(25
)
(14
)
Net sales
2,556
2,752
2,337
9,544
2,204
2,419
2,532
2,389
___________________________
(1)
Includes intersegment sales primarily related to the Acetyl Chain.
Table 4a
Factors Affecting Segment Net Sales Sequentially - Unaudited
Three Months Ended September 30, 2026 Compared to Three Months Ended June 30, 2026
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(7
)
2
—
(5
)
Acetyl Chain
(4
)
(5
)
—
(9
)
Total Company
(5
)
(2
)
—
(7
)
Three Months Ended June 30, 2026 Compared to Three Months Ended March 31, 2026
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
3
6
—
9
(1)
Acetyl Chain
6
22
—
28
Total Company
4
14
—
18
Three Months Ended March 31, 2026 Compared to Three Months Ended December 31, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
3
—
1
4
Acetyl Chain
8
1
1
10
Total Company
5
—
1
6
Three Months Ended December 31, 2025 Compared to Three Months Ended September 30, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(6
)
(2
)
—
(8
)
Acetyl Chain
(10
)
(1
)
—
(11
)
Total Company
(7
)
(2
)
—
(9
)
Three Months Ended September 30, 2025 Compared to Three Months Ended June 30, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(6
)
1
1
(4
)
Acetyl Chain
(2
)
(4
)
1
(5
)
Total Company
(4
)
(1
)
1
(4
)
Three Months Ended June 30, 2025 Compared to Three Months Ended March 31, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
9
—
3
12
Acetyl Chain
(1
)
(2
)
3
—
Total Company
4
(1
)
3
6
Three Months Ended March 31, 2025 Compared to Three Months Ended December 31, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
—
2
(1
)
1
Acetyl Chain
3
(1
)
(1
)
1
Total Company
2
—
(1
)
1
______________________________
(1)
Includes a (4), 0, and 0 percent net sales impact of volume, price, and currency, respectively, as a result of the sale of the Micromax ® business.
Table 4b
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(6
)
5
—
(1
)
(1)
Acetyl Chain
—
14
—
14
Total Company
(4
)
10
—
6
Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(6
)
5
1
—
(2)
Acetyl Chain
—
18
1
19
Total Company
(3
)
11
1
9
Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
—
(1
)
4
3
Acetyl Chain
(7
)
(4
)
4
(7
)
Total Company
(3
)
(3
)
4
(2
)
Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(2
)
—
3
1
Acetyl Chain
(10
)
(7
)
2
(15
)
Total Company
(6
)
(3
)
2
(7
)
Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(8
)
(1
)
2
(7
)
Acetyl Chain
(4
)
(8
)
1
(11
)
Total Company
(6
)
(4
)
1
(9
)
Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(3
)
(1
)
2
(2
)
Acetyl Chain
(2
)
(7
)
2
(7
)
Total Company
(2
)
(4
)
2
(4
)
Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(4
)
(2
)
(1
)
(7
)
Acetyl Chain
(6
)
(4
)
(1
)
(11
)
Total Company
(5
)
(3
)
(1
)
(9
)
______________________________
(1)
Includes a (6), 0, and 0 percent net sales impact of volume, price, and currency, respectively, as a result of the sale of the Micromax ® business.
(2)
Includes a (6), 0, and 0 percent net sales impact of volume, price, and currency, respectively, as a result of the sale of the Micromax ® business.
Table 4c
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Year Ended December 31, 2025 Compared to Year Ended December 31, 2024
Volume
Price
Currency
Total
(In percentages)
Engineered Materials
(4
)
(1
)
1
(4
)
Acetyl Chain
(6
)
(6
)
1
(11
)
Total Company
(4
)
(4
)
1
(7
)
Table 5
Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions, except percentages)
Net cash provided by (used in) investing activities
(70
)
(59
)
425
(349
)
(104
)
(59
)
(88
)
(98
)
Net cash provided by (used in) financing activities
(480
)
(546
)
(3
)
(513
)
(324
)
(118
)
(116
)
45
Net cash provided by (used in) operating activities
538
209
76
1,146
252
447
410
37
Capital expenditures on property, plant and equipment
(69
)
(62
)
(66
)
(343
)
(84
)
(64
)
(93
)
(102
)
Contributions from/(Distributions) to NCI
(8
)
(7
)
(7
)
(30
)
(8
)
(8
)
(6
)
(8
)
Free cash flow (1)
461
140
3
773
160
375
311
(73
)
Net sales
2,556
2,752
2,337
9,544
2,204
2,419
2,532
2,389
Free cash flow as % of Net sales
18.0
%
5.1
%
0.1
%
8.1
%
7.3
%
15.5
%
12.3
%
(3.1
)%
______________________________
(1)
Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures.
Table 6
Cash Dividends Received - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions)
Dividends from equity method investments
—
16
54
139
47
40
21
31
Dividends from equity investments without readily determinable fair values
44
43
1
122
40
40
41
1
Total
44
59
55
261
87
80
62
32
Table 7
Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
(In $ millions)
Short-term borrowings and current installments of long-term debt - third party and affiliates
1,414
1,311
1,741
1,204
1,204
1,199
252
406
Long-term debt, net of unamortized deferred financing costs
10,131
10,696
10,813
11,394
11,394
11,655
12,689
12,378
Total debt
11,545
12,007
12,554
12,598
12,598
12,854
12,941
12,784
Cash and cash equivalents
(1,362
)
(1,364
)
(1,758
)
(1,263
)
(1,263
)
(1,440
)
(1,173
)
(951
)
Net debt
10,183
10,643
10,796
11,335
11,335
11,414
11,768
11,833
Table 8
Certain Items - Unaudited
The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:
Q3 '26
Q2 '26
Q1 '26
2025
Q4 '25
Q3 '25
Q2 '25
Q1 '25
Income Statement Classification
(In $ millions)
Exit and shutdown costs
87
121
44
98
29
10
27
32
Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Equity in net earnings (loss) of affiliates / Research & development expenses
Asset impairments
—
—
—
1,513
27
(1)
1,486
(2)
—
—
Other (charges) gains, net
Impact from plant incidents and natural disasters
—
—
11
3
—
—
—
3
Cost of sales
Mergers, acquisitions and dispositions
12
35
15
52
23
12
12
5
Cost of sales / SG&A / Other income (expense), net / Gain (loss) on disposition of assets, net / Research & development expenses
Actuarial (gain) loss on pension and postretirement plans
—
—
—
(49
)
(49
)
—
—
—
Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income
Legal settlements and commercial disputes
10
4
3
17
1
11
2
3
SG&A
(Gain) loss on disposition of businesses and assets
—
(4
)
(50
)
—
—
—
—
—
Gain (loss) on disposition of businesses and assets, net
Other
—
—
—
5
3
1
1
—
Cost of sales
Certain Items attributable to Celanese Corporation
109
156
23
1,639
34
1,520
42
43
___________________________
(1)
Related to impairment of certain long-lived assets arising from unused parcels of property subsequently sold.
(2)
Related to impairment of goodwill and certain trade names, primarily Zytel ® , arising from our annual goodwill and indefinite-lived intangible assets impairment tests.
Table 9
Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited
2025
(In $ millions, except percentages)
Net earnings (loss) attributable to Celanese Corporation
(1,165
)
Adjusted EBIT (Table 1)
1,150
Adjusted effective tax rate (Table 3a)
8
%
Adjusted EBIT tax effected
1,058
2025
2024
Average
(In $ millions, except percentages)
Short-term borrowings and current installments of long-term debt - third parties and affiliates
1,204
1,501
1,353
Long-term debt, net of unamortized deferred financing costs
11,394
11,078
11,236
Celanese Corporation shareholders' equity
4,049
5,129
4,589
Invested capital
17,178
Return on invested capital (adjusted)
6.2
%
Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital
(6.8
)%
View source version on businesswire.com: https://www.businesswire.com/news/home/20261030697093/en/
Investor Relations
Bill Cunningham
Phone: +1 302 772 5231
william.cunningham@celanese.com
Media – U.S.
Jamaison Schuler
Phone: +1 972 443 4400
media@celanese.com
Media – Europe
Petra Czugler
Phone: +49 69 45009 1206
petra.czugler@celanese.com
Media – Asia
Maria Xia
Phone: +86 21 3861 9368
maria.xia@celanese.com
Source: Celanese Corporation